The renin-angiotensin system: Where do we stand, and what is the future?

American Journal of Hypertension

Volumn 18, Issue 9 SUPPL., 2005, Pages 125-126

  Hamet, Pavel ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 23944491347     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.05.003     Document Type: Article

References (21)

1. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
2. B. Brown, A. Hall Renin-angiotensin system modulation the weight of evidence Am J Hypertens 18 2005 127S 133S
3. HOPE Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
4. EUROPA Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
5. L. Pilote, M. Abrahamowicz, E. Rodrigues, M.J. Eisenberg, E. Rahme Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction a class effect? Ann Intern Med 141 2004 102 112
6. S. Hennessy Is improved survival a class effect of angiotensin-converting enzyme inhibitors? Ann Intern Med 141 2004 157 158
7. PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
8. S. Yusuf, J. Pogue ACE inhibition in stable coronary artery disease N Engl J Med 352 2005 937 939
9. R. Ferrari, G. Pasanisi, P. Notarstefano, G. Campo, E. Gardini, C. Ceconi Jr Specific properties and effect of perindopril in controlling the renin-angiotensin system Am J Hypertens 18 2005 142S 154S
10. S. Laurent Evidence for benefits of perindopril in hypertension and its complications Am J Hypertens 18 2005 155S 162S
11. N.K. Thybo, N. Stephens, A. Cooper, C. Aalkjaer, A.M. Heagerty, M.J. Mulvany Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension Hypertension 25 1995 474 481
12. N.H. Buus, M. Botthcer, C.G. Jorgensen, K.L. Christensen, K. Thygesen, T.T. Nielsen, M.J. Mulvany Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension Hypertension 44 2004 465 470
13. P. Hamet, S.N. Orlov, D. deBlois, Y. Sun, V. Kren, J. Tremblay Angiotensin as a cytokine implicated in accelerated cellular turnover T. Unger B.A. Schölkens Handbook of Experimental Pharmacology, Volume 163/I, Angiotensin Volume 1 2004 Berlin Springer Verlag 71 98
14. S. Der Sarkissian, E.-L. Marchand, D. Duguay, P. Hamet, D. deBlois Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril Cardiovasc Res 57 2003 775 783
15. B.I. Levy How to explain the differences between renin angiotensin system modulators Am J Hypertens 18 2005 134S 141S
16. M.A. Crackower, R. Sarao, G.Y. Oudit, G.Y. Yagil, C. Yagil, I. Kozieradzki, S.E. Scanga, A.J. Oliveira-dos-Santos, J. da Costa, L. Zhang, Y. Pei, J. Scholey, C.M. Ferrario, A.S. Manoukian, M.C. Chappell, P.H. Backx, Y. Yagil, J.M. Penninger Angiotensin-converting enzyme 2 is an essential regulator of heart function Nature 417 2002 822 828
17. M.M. Kittleson, K.M. Minhas, R.A. Irizarry, S.Q. Ye, G. Edness, E. Breton, J.V. Conte, G. Tomaselli, J.G. Garcia, J.M. Hare Gene expression analysis of ischemic and nonischemic cardiomyopathy shared and distinct genes in the development of heart failure Physiol Genomics 21 2005 299 307 [Epub 2005 Mar 15, 2005]
18. M. Igase, W.B. Strawn, P.E. Gallagher, R.L. Geary, C.M. Ferrario Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in aorta of spontaneously hypertensive rats Am J Physiol Heart Circ Physiol 2005 April 15. (Epub ahead of print)
19. P. Hamet, E. Merlo, O. Seda, U. Broeckel, J. Tremblay, M. Kaldunski, D. Gaudet, G. Bouchard, B. Deslauriers, F. Gagnon, G. Antoniol, Z. Pausova, M. Labuda, M. Jomphe, F. Gossard, G. Tremblay, R. Kirova, P. Tonellato, S.N. Orlov, J. Pintos, J. Platko, T.J. Hudson, J.D. Rioux, T.A. Kotchen, A.W. Cowley Quantitative founder effect analysis of French-Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension Am J Hum Genet 76 2005 815 832
20. M. Labuda, J. Uwabo, Y. Sun, D. Gaudet, F. Gossard, Z. Pausova, T. Kotchen, A.W. Cowley, J. Tremblay, P. Hamet Polymorphism in ACE2 gene is associated with hypertension and hypertension-related phenotypes in French-Canadians Can J Cardiol 20 Suppl D 2004 48D
21. A.D. Roses Pharmacogenetics and drug development the path to safer and more effective drugs Nat Rev Genet 5 2004 645 656